Skip to main content

This is a preprint.

It has not yet been peer reviewed by a journal.

The National Library of Medicine is running a pilot to include preprints that result from research funded by NIH in PMC and PubMed.

bioRxiv logoLink to bioRxiv
[Preprint]. 2024 Dec 12:2024.12.09.627518. [Version 1] doi: 10.1101/2024.12.09.627518

Patient-Derived Xenografts of Triple-Negative Breast Cancer Enable Deconvolution and Prediction of Chemotherapy Responses

Jonathan T Lei, Lacey E Dobrolecki, Chen Huang, Ramakrishnan R Srinivasan, Suhas V Vasaikar, Alaina N Lewis, Christina Sallas, Na Zhao, Jin Cao, John D Landua, Chang In Moon, Yuxing Liao, Susan G Hilsenbeck, C Kent Osborne, Mothaffar F Rimawi, Matthew J Ellis, Varduhi Petrosyan, Bo Wen, Kai Li, Alexander B Saltzman, Antrix Jain, Anna Malovannaya, Gerburg M Wulf, Elisabetta Marangoni, Shunqiang Li, Daniel C Kraushaar, Tao Wang, Senthil Damodaran, Xiaofeng Zheng, Funda Meric-Bernstam, Gloria V Echeverria, Meenakshi Anurag, Xi Chen, Bryan E Welm, Alana L Welm, Bing Zhang, Michael T Lewis
PMCID: PMC11661147  PMID: 39713418

Summary

Combination chemotherapy remains essential for clinical management of triple-negative breast cancer (TNBC). Consequently, responses to individual agents cannot be easily delineated at the single patient level, even though some patients might not require all drugs in the combination. Herein, we conduct multi-omic analyses of orthotopic TNBC patient-derived xenografts (PDXs) treated with single agent carboplatin, docetaxel, or the combination. Combination responses were usually no better than the best single agent, with enhanced response in only ∼13% of PDX, and apparent antagonism in a comparable percentage. Single-omic comparisons showed largely non-overlapping results between genes associated with single agent and combination treatments that could be validated in independent patient cohorts. Multi-omic analyses of PDXs identified agent-specific biomarkers/biomarker combinations, nominating high Cytokeratin-5 (KRT5) as a general marker of responsiveness. Notably, integrating proteomic with transcriptomic data improved predictive modeling of pathologic complete response to combination chemotherapy. PDXs refractory to all treatments were enriched for signatures of dysregulated mitochondrial function. Targeting this process indirectly in a PDX with HDAC inhibition plus chemotherapy in vivo overcomes chemoresistance. These results suggest possible resistance mechanisms and therapeutic strategies in TNBC to overcome chemoresistance, and potentially allow optimization of chemotherapeutic regimens.

Highlights

  1. Minable multi-omic resource of baseline TNBC PDX tumors matched with single and combination chemotherapy responses yields candidate resistance mechanisms and potentially targetable processes

  2. Combination carboplatin/docetaxel is largely ineffective at enhancing response versus the best single agent in TNBC PDXs, and they can antagonize one another in some PDXs

  3. Proteomics data enhances predictions of platinum- and taxane-based chemotherapy response

  4. Targeted agents can enhance chemotherapy response in TNBC PDXs

Full Text

The Full Text of this preprint is available as a PDF (37.3 MB). The Web version will be available soon.


Articles from bioRxiv are provided here courtesy of Cold Spring Harbor Laboratory Preprints

RESOURCES